Menu Search
Equities

Abingdon Health PLC

ABDXF:PKC

Abingdon Health PLC

Actions
  • Price (USD)0.07
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Aug 19 2022.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Abingdon Health plc provides lateral flow contract development and manufacturing (CDMO services) and related contract services to an international customer base. It offers its services to an international customer base across industry sectors, which include clinical, self-testing, animal health, plant health, and environmental testing. Its segments include Product sales, Contract manufacturing, Contract development, and Regulatory. Its regulatory services include technical file build, regulatory filing support, implementation of quality management systems and quality assurance. The Company’s CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Its Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to enable consumers to manage their own health and wellbeing.

  • Revenue in GBP (TTM)5.34m
  • Net income in GBP-2.24m
  • Incorporated2008
  • Employees82.00
  • Location
    Abingdon Health PLCYork Biotech Campus, Sand HuttonYORK YO41 1LZUnited KingdomGBR
  • Phone+44 190 440 6050
  • Fax+44 190 446 2122
  • Websitehttps://www.abingdonhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.